A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Jiangsu Cancer Institute & Hospital
National Cancer Institute (NCI)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Centre Oscar Lambret
Neonc Technologies, Inc.
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
Abramson Cancer Center at Penn Medicine
Jiangsu Cancer Institute & Hospital
AHS Cancer Control Alberta
University of Rochester
Merck Sharp & Dohme LLC
Fujian Cancer Hospital
Washington University School of Medicine
Shanghai Chest Hospital